Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

NCT04675294 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: evorpacept
DRUG: pembrolizumab

Sponsor

ALX Oncology Inc.

Collaborators

[object Object]